Not available
Quote | HUTCHMED (China) Limited (NASDAQ:HCM)
Last: | $20.96 |
---|---|
Change Percent: | 4.59% |
Open: | $20.56 |
Close: | $20.96 |
High: | $21.05 |
Low: | $20.49 |
Volume: | 119,496 |
Last Trade Date Time: | 05/16/2024 03:00:00 am |
News | HUTCHMED (China) Limited (NASDAQ:HCM)
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data rela...
— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED’s surufatinib and anti-PD-1 activity with Hengrui...
Message Board Posts | HUTCHMED (China) Limited (NASDAQ:HCM)
Subject | By | Source | When |
---|---|---|---|
The now last up | MWM | investorshub | 05/10/2023 3:35:25 PM |
$HCM Time for this to show some returns | MWM | investorshub | 05/08/2023 7:41:07 PM |
$HCM MomentumIts gaining | crowin | investorshub | 05/08/2023 7:12:07 AM |
short squeeze | MWM | investorshub | 05/08/2023 1:11:22 AM |
$HCM The trading last up | MWM | investorshub | 05/07/2023 6:33:31 AM |
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
4.59%Change Percent:
HUTCHMED (China) Limited Company Name:
HCM Stock Symbol:
NASDAQ Market:
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) tod...
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data rela...
— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED’s surufatinib and anti-PD-1 activity with Hengrui...